Comparing immediate surgery and neoadjuvant chemotherapy for pancreatic cancer treatment
Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer
Minia University · NCT06978322
This study is testing if giving chemotherapy before surgery helps people with pancreatic cancer live longer and have better outcomes than having surgery right away.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Minia University (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Minya) |
| Trial ID | NCT06978322 on ClinicalTrials.gov |
What this trial studies
This trial investigates whether neoadjuvant chemotherapy improves overall survival in patients with resectable pancreatic cancer compared to immediate surgery, both followed by adjuvant chemotherapy. The study aims to address the poor treatment outcomes associated with pancreatic cancer by evaluating the effectiveness of pre-surgical chemotherapy. It focuses on increasing the rate of successful surgical resections and identifying patients who may not benefit from surgery due to rapid disease progression.
Who should consider this trial
Good fit: Ideal candidates are patients with histopathologically confirmed resectable pancreatic cancer who are fit for surgery.
Not a fit: Patients with borderline resectable, locally advanced, or metastatic pancreatic cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved survival rates for patients with resectable pancreatic cancer.
How similar studies have performed: Other studies have shown promising results with neoadjuvant therapies in similar contexts, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Computed tomography (CT) with pancreatic protocol + vascular mapping * Histopathologically proven malignant by CT-guided or endoscopic ultrasound (EUS)-guided biopsy Resectable pancreatic cancer means no contact of the tumor with the Superior mesenteric artery, Celiac axis \& Common hepatic artery, and contact of the tumor but ≤90° contact with the superior mesenteric vein \& portal vein. Exclusion Criteria: * Borderline resectable \& locally advanced pancreatic cancer * Tumor at the tail of the pancreas. * Metastatic pancreatic cancer * Unfit patients for surgery.
Where this trial is running
Minya
- Minia University — Minya, Egypt (RECRUITING)
Study contacts
- Study coordinator: Abdelrahman M Salah, MD
- Email: Abdelrahman.salah@mu.edu.eg
- Phone: 00201064746493
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Surgery, Neoadjuvant Chemotherapy, Management, Resectable Pancreatic Cancer